CYP2D6 acts on 25% of all prescription drugs.  Approximately 4-7% of the population has a slow acting form of this enzyme and 3% a super-fast acting form. About 35% of the population are carriers of a non-functional CYP2D6 allele, which especially elevates the risk of adverse drug events (ADEs) when these individuals are taking multiple drugs.
Drugs that CYP2D6 metabolizes include selective serotonin reuptake inhibitors (SSRI), tricyclic antidepressants (TCA), beta-blockers, opiates, neuroleptics, antiarrhythmics, and a variety of toxic plant substances.
Genelex offers improved detection rates using an extended Cytochrome P450 2D6 DNA mutation panel. This CYP2D6 test identifies 25 variants of the more common alleles (*2,*2A,*3-*12,*14,*15,*17,*19,*20,*21,*29,*30,*35,*36,*41,*56,*109), gene deletions, gene duplications and gene rearrangements in PCR-multiplex format, providing increased sensitivity and quality performance. Copy number and gene re-arrangement determinations may not always be determined. This CYP2D6 Mutation Detection Panel is the most extensive on the market and covers over 93-97% of poor metabolizer phenotypes. Analytical specificity and sensitivity for detection of these mutations are >99%.
Indication for CYP2D6 Testing
For individuals with a personal or family history of adverse drug reactions to medications metabolized by CYP2D6.